Effect of osteopontin on TIMP‑1 and TIMP‑2 mRNA in chondrocytes of human knee osteoarthritis in vitro

Zhang,Fang‑Jie; Yu,Wen‑Bo; Luo,Wei; Gao,Shu‑Guang; Li,Yu‑Sheng; Lei,Guang‑Hua

doi:10.3892/etm.2014.1750

Effect of osteopontin on TIMP‑1 and TIMP‑2 mRNA in chondrocytes of human knee osteoarthritis in vitro

Authors:
- Fang‑Jie Zhang
- Wen‑Bo Yu
- Wei Luo
- Shu‑Guang Gao
- Yu‑Sheng Li
- Guang‑Hua Lei
View Affiliations

Affiliations: Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: May 29, 2014 https://doi.org/10.3892/etm.2014.1750
Pages: 391-394

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tissue inhibitors of metalloproteinases (TIMPs) regulate the activity of matrix metalloproteinases (MMPs) and enzymes from the a disintegrin and metalloproteinase domain with thrombospondin motifs family in osteoarthritis (OA). Elevated osteopontin (OPN) levels in plasma, synovial ﬂuid and articular cartilage are associated with progressive OA joint damage; however, the role of OPN in the pathological changes of knee OA remains undetermined. The present study was undertaken to examine the effect of OPN on the expression of TIMP‑1 and TIMP‑2 mRNA in chondrocytes from 16 patients with knee OA. In this study, following the stimulation of human chondrocytes with recombinant human OPN (rhOPN; 100 ng/ml and 1 µg/ml, respectively) for 48 h, MTT assay was used to determine cell viability while the quantitative polymerase chain reaction (PCR) was used to detect the alterations in TIMP‑1 and TIMP‑2 levels. The results illustrated that neither 100 ng/ml nor 1 µg/ml rhOPN caused cytotoxicity or apoptosis of chondrocytes and that the relative mRNA expression of TIMP‑1 and TIMP‑2 was signiﬁcantly increased in the 1 µg/ml rhOPN group compared with that in the control group (P=0.022 and P=0.003, respectively). However, no signiﬁcant difference in expression was revealed between the 100 ng/ml rhOPN and control groups (P=0.998 and P=0.209, respectively). In conclusion, OPN may have a protective effect against pathological changes in advanced‑stage OA.

View Figures

View References

1	Roughley PJ: Articular cartilage and changes in arthritis: noncollagenous proteins and proteoglycans in the extracellular matrix of cartilage. Arthritis Res. 3:342–347. 2001. View Article : Google Scholar : PubMed/NCBI
2	Eyre D: Collagen of articular cartilage. Arthritis Res. 4:30–35. 2002. View Article : Google Scholar
3	Davidson RK, Waters JG, Kevorkian L, Darrah C, Cooper A, Donell ST and Clark IM: Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther. 8:R1242006. View Article : Google Scholar : PubMed/NCBI
4	Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS and Woessner JF Jr: Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest. 84:678–685. 1989. View Article : Google Scholar : PubMed/NCBI
5	Hughes CE, Little CB, Büttner FH, Bartnik E and Caterson B: Differential expression of aggrecanase and matrix metalloproteinase activity in chondrocytes isolated from bovine and porcine articular cartilage. J Biol Chem. 273:30576–30582. 1998. View Article : Google Scholar : PubMed/NCBI
6	Pullig O, Weseloh G, Gauer S and Swoboda B: Osteopontin is expressed by adult human osteoarthritic chondrocytes: protein and mRNA analysis of normal and osteoarthritic cartilage. Matrix Biol. 19:245–255. 2000. View Article : Google Scholar : PubMed/NCBI
7	McKee MD, Glimcher MJ and Nanci A: High-resolution immunolocalization of osteopontin and osteocalcin in bone and cartilage during endochondral ossification in the chicken tibia. Anat Rec. 234:479–492. 1992. View Article : Google Scholar : PubMed/NCBI
8	Honsawek S, Tanavalee A, Sakdinakiattikoon M, Chayanupatkul M and Yuktanandana P: Correlation of plasma and synovial fluid osteopontin with disease severity in knee osteoarthritis. Clin Biochem. 42:808–812. 2009. View Article : Google Scholar : PubMed/NCBI
9	Gao SG, Li KH, Zeng KB, Tu M, Xu M and Lei GH: Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients. Osteoarthritis Cartilage. 18:82–87. 2010. View Article : Google Scholar : PubMed/NCBI
10	Attur MG, Dave MN, Stuchin S, Kowalski AJ, Steiner G, Abramson SB, Denhardt DT and Amin AR: Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum. 44:578–584. 2001. View Article : Google Scholar : PubMed/NCBI
11	Matsui Y, Iwasaki N, Kon S, Takahashi D, Morimoto J, Matsui Y, Denhardt DT, Rittling S, Minami A and Uede T: Accelerated development of aging-associated and instability-induced osteoarthritis in osteopontin-deficient mice. Arthritis Rheum. 60:2362–2371. 2009. View Article : Google Scholar : PubMed/NCBI
12	Pelletier JP, Mineau F, Faure MP and Martel-Pelletier J: Imbalance between the mechanisms of activation and inhibition of metalloproteases in early lesions of experimental osteoarthritis. Arthritis Rheum. 33:1466–1476. 1990. View Article : Google Scholar : PubMed/NCBI
13	Knäuper V, López-Otin C, Smith B, Knight G and Murphy G: Biochemical characterization of human collagenase-3. J Biol Chem. 271:1544–1550. 1996.
14	Tetlow LC, Adlam DJ and Woolley DE: Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum. 44:585–594. 2001. View Article : Google Scholar : PubMed/NCBI
15	Dean DD and Woessner JF Jr: Extracts of human articular cartilage contain an inhibitor of tissue metalloproteinases. Biochem J. 218:277–280. 1984.PubMed/NCBI
16	Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S and He CS: Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci USA. 86:8207–8211. 1989. View Article : Google Scholar : PubMed/NCBI
17	Chevalier X, Conrozier T, Gehrmann M, Claudepierre P, Mathieu P, Unger S and Vignon E: Tissue inhibitor of metalloprotease-1 (TIMP-1) serum level may predict progression of hip osteoarthritis. Osteoarthritis Cartilage. 9:300–307. 2001. View Article : Google Scholar : PubMed/NCBI
18	Petrow PK, Hummel KM, Schedel J, Franz JK, Klein CL, Müller-Ladner U, Kriegsmann J, Chang PL, Prince CW, Gay RE and Gay S: Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum. 43:1597–1605. 2000. View Article : Google Scholar : PubMed/NCBI
19	Ohshima S, Kobayashi H, Yamaguchi N, Nishioka K, Umeshita-Sasai M, Mima T, Nomura S, Kon S, Inobe M, Uede T and Saeki Y: Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum. 46:1094–1101. 2002. View Article : Google Scholar : PubMed/NCBI